5-MAPBT

Uses your system voice; voice and rate in settings.

Snapshot

≈ 3 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

5-MAPBT, also known as 5-(2-(methylamino)propyl)-1-benzothiophene, is a possible entactogen of the phenethylamine, amphetamine, and benzothiophene families. It is closely related to 5-MAPB, but with the oxygen atom replaced by sulfur, changing the core ring structure to benzothiophene rather than benzofuran. The drug acts as a potent monoamine releasing agent, including of serotonin and dopamine, and as a potent serotonin 5-HT 1B receptor agonist and serotonin 5-HT 2B receptor antagonist. It is also a monoamine oxidase A (MAO-A) inhibitor, with an of 765 nM. It produces anxiolytic-like and antiobsessional-like effects in the marble burying test in rodents. However, benzothiophenes like 5-MAPBT, despite their induction of dopamine release, are said to lack hyperlocomotion or stimulant-like effects in rodents. 5-MAPBT has been studied and patented by Matthew J. Baggott at Tactogen. The drug has also been patented by Mydecine and given the developmental code name MY400.

5-MAPBT, also known as 5-(2-(methylamino)propyl)-1-benzothiophene, is a possible entactogen of the phenethylamine, amphetamine, and benzothiophene families. It is closely related to 5-MAPB, but with the oxygen atom replaced by sulfur, changing the core ring structure to benzothiophene rather than benzofuran. The drug acts as a potent monoamine releasing agent, including of serotonin and dopamine, and as a potent serotonin 5-HT 1B receptor agonist and serotonin 5-HT 2B receptor antagonist. It is also a monoamine oxidase A (MAO-A) inhibitor, with an of 765 nM. It produces anxiolytic-like and antiobsessional-like effects in the marble burying test in rodents. However, benzothiophenes like 5-MAPBT, despite their induction of dopamine release, are said to lack hyperlocomotion or stimulant-like effects in rodents. 5-MAPBT has been studied and patented by Matthew J. Baggott at Tactogen. The drug has also been patented by Mydecine and given the developmental code name MY400.

See also

Substituted benzothiophene 6-MAPBT BK-5-MAPBT 5-MAPDI BK-5-MAPB IBF5MAP MDMA Methamnetamine TDMA

References

External links

5-MAPBT - Isomer Design

Text derived from https://en.wikipedia.org/w/index.php?oldid=1329693338 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

Extracted from the cited revision's reference blocks; absent citations are not invented.